Landos Biopharma (NASDAQ:LABP) Shares Gap Up to $13.83

Landos Biopharma, Inc. (NASDAQ:LABP)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $13.83, but opened at $14.33. Landos Biopharma shares last traded at $14.30, with a volume of 4 shares changing hands.

LABP has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Landos Biopharma from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Wednesday, July 28th. Raymond James lifted their price objective on shares of Landos Biopharma from $33.00 to $35.00 and gave the company an “outperform” rating in a research report on Friday, July 30th. Finally, SVB Leerink initiated coverage on Landos Biopharma in a report on Friday, July 30th. They issued a “buy” rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Landos Biopharma presently has a consensus rating of “Buy” and an average target price of $23.20.

The company has a market cap of $601.37 million and a price-to-earnings ratio of -6.07. The business has a fifty day simple moving average of $12.60 and a 200 day simple moving average of $11.93.

Landos Biopharma (NASDAQ:LABP) last released its quarterly earnings results on Wednesday, July 28th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.26. Research analysts forecast that Landos Biopharma, Inc. will post -1.28 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in LABP. Perceptive Advisors LLC acquired a new position in shares of Landos Biopharma during the 1st quarter worth $159,688,000. RTW Investments LP acquired a new position in Landos Biopharma in the 1st quarter valued at about $38,328,000. Logos Global Management LP acquired a new position in Landos Biopharma in the 1st quarter valued at about $7,068,000. Orbimed Advisors LLC acquired a new position in Landos Biopharma in the 1st quarter valued at about $6,558,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in Landos Biopharma in the 1st quarter valued at about $4,334,000. 56.63% of the stock is owned by institutional investors and hedge funds.

Landos Biopharma Company Profile (NASDAQ:LABP)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases.

Recommended Story: What is basic economics?

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.